Alnylam Pharmaceuticals, Inc.
ALNY· Nasdaq
ALNYAlnylam Pharmaceuticals, Inc.
Filed Apr 28, 2022 · 10-Q · 28 days after period end · 0001178670-22-000016
| Metric | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|
| Revenue | $213.26M | $177.57M | $99.48M | $33.29M |
| Net Income | -$240.34M | -$200.29M | -$182.22M | -$181.92M |
| EPS Diluted | -$2.00 | -$1.71 | -$1.62 | -$1.73 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Alnylam Pharmaceuticals, Inc. · CIK 1178670 · Engraved from SEC EDGAR
ended Mar 31, 2022 · filed Apr 28, 2022 · 28 d after period end
